FDI Perspective: TAKEDA
Japan’s biggest pharmaceutical company has two production plants in Germany: one in Baden-Württemberg, which is working on a dengue fever vaccine, and another in Oranienburg.
Takeda has been active in Germany since the 1980s, but the country became one of the Japanese pharmaceutical giant’s key global locations in 2011, when it acquired the Swiss company Nycomed.
German Chancellor Angela Merkel opens the new Takeda production hall in Oranienburg in 2017.
© picture alliance/Ralf Hirschberger/dpa-Zentralbild/dpa
That gave Takeda two major manufacturing plants in Germany – in the town of Singen in the south and near Berlin in the northeast. Both locations have a decades-long tradition of manufacturing medicine. Today, Takeda employs some 2,500 people in Germany. They specialize in the production of high-quality medication that reaches patients in more than 100 countries around the world. Takeda has expanded substantially in Germany in the past few years, investing more than EUR 300 million.
This money went toward increasing capacity at the Oranienburg plant by 50 percent in 2017, while the Singen plant is about to become Takeda’s first site to produce a dengue fever vaccine. Takeda’s production was not slowed by the coronavirus pandemic.
employees in Germany
invested in German sites in recent years
was the year Takeda launched in Germany